Affimed Announces Annual General Meeting of Shareholders
May 22 2017 - 09:46AM
Heidelberg, Germany, May 22, 2017 - Affimed N.V.
(Nasdaq: AFMD), a clinical stage biopharmaceutical company focused
on discovering and developing highly targeted cancer
immunotherapies, announced today that the Annual General Meeting of
Shareholders will be held on Tuesday, June 20, 2017. The meeting
will be held at Hilton Amsterdam, Apollolaan 138, 1077 BG
Amsterdam, The Netherlands. The meeting will start at 2:30 p.m.
CET.
The notice and agenda of the general meeting are
available free of charge in the Investor Relations section under
"Notice to convene the Annual General Meeting of Shareholders of
Affimed N.V." of Affimed's corporate website at www.affimed.com.
They are also available on the SEC's website at www.sec.gov.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK- and T-cells). We are
developing single and combination therapies to treat cancers and
other life-threatening diseases. For more information, please visit
www.affimed.com.
IR Contact:
Caroline Stewart, Head IRPhone: +1 347394 6793E-Mail:
IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of CommunicationsPhone: +49 6221
64793341E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2023 to Mar 2024